These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12036416)

  • 1. Review of raloxifene and its clinical applications in osteoporosis.
    Maricic M; Gluck O
    Expert Opin Pharmacother; 2002 Jun; 3(6):767-75. PubMed ID: 12036416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene: recent information on skeletal and non-skeletal effects.
    Gluck O; Maricic M
    Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal and nonskeletal effects of raloxifene.
    Gluck O; Maricic M
    Curr Osteoporos Rep; 2003 Dec; 1(3):123-8. PubMed ID: 16036075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raloxifene: a review of its use in the prevention of invasive breast cancer.
    Moen MD; Keating GM
    Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS; Jordan VC
    Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene for older women: a review of the literature.
    Hansdóttir H
    Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
    Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal effects of selective oestrogen receptor modulators (SERMs).
    Díez JL
    Hum Reprod Update; 2000; 6(3):255-8. PubMed ID: 10874570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
    Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
    Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of raloxifene hydrochloride.
    Saitta A; Morabito N; Frisina N; Cucinotte D; Corrado F; D'Anna R; Altavilla D; Squadrito G; Minutoli L; Arcoraci V; Cancellieri F; Squadrito F
    Cardiovasc Drug Rev; 2001; 19(1):57-74. PubMed ID: 11314601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene in breast cancer prevention.
    Gennari L; Merlotti D; Paola VD; Nuti R
    Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene hydrochloride.
    Snyder KR; Sparano N; Malinowski JM
    Am J Health Syst Pharm; 2000 Sep; 57(18):1669-75; quiz 1676-8. PubMed ID: 11006795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
    Štěpán J; Rosa J; Pavelka K
    Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB
    Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Raloxifene and breast: from the SERMs concept to its place in clinical practice].
    This P; Guyot B
    Gynecol Obstet Fertil; 2004 Jan; 32(1):75-84. PubMed ID: 14736604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
    Kobayashi H; Hamaya E
    Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.